Log In Sign up
The largest database of trusted experimental protocols

Be0031

Manufactured by BioXCell
Visit Supplier

BE0031 is a benchtop centrifuge capable of reaching speeds up to 15,000 RPM. It features a rotor with a capacity of 6 x 50 mL conical tubes. The centrifuge is designed for general-purpose applications in the laboratory setting.

Automatically generated - may contain errors

Lab products found in correlation

Be0061, by BioXCell (1 mentions) Be0012, by BioXCell (1 mentions) Be0131, by BioXCell (1 mentions) Poly 1 c adjuvant, by InvivoGen (1 mentions) Syrian hamster igg, by BioXCell (1 mentions) Rat igg2a, by BioXCell (1 mentions) Yts 169, by BioXCell (1 mentions) Be0213, by BioXCell (1 mentions) Be0090, by BioXCell (1 mentions) Afs98, by BioXCell (1 mentions) Be0117, by BioXCell (1 mentions)

4 protocols using be0031

1

OX40 Agonist Antibody for Immunotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols
To stimulate the OX40 pathway, we utilized an agonistic antibody, anti-OX40/CD134 (Bio X Cell InVivoMAb #BE0031) or IgG1 isotype control (clone HRPN, Bio X Cell InVivoMAb #BE0088). Mice were treated twice a week with antibody on a 2 weeks on/off cycle. An intermittent dosing schedule for was used CDK4/6i + MEKi, as outlined above.
Teh J.L., Erkes D.A., Cheng P.F., Tiago M., Wilski N.A., Field C.O., Chervoneva I., Levesque M.P., Xu X., Dummer R, & Aplin A.E. (2020). Activation of CD8+ T cells contributes to antitumor effects of CDK4/6 inhibitors plus MEK inhibitors. Cancer immunology research, 8(9), 1114-1121.
+ Open protocol
+ Expand
2

T-cell and Treg Depletion Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
For T-cell depletion, 1 week after TAM and every 5 d, 200 μg CD4 (clone GK1.5; BE003–1, BioXCell) and CD8 (clone 2.43; BE0061, BioXCell) antibodies were injected intraperitoneally into Atg7Δ/Δ and Atg7+/+ mice. At 2 d after the first antibody injection, MB49 (0.25 × 106 cells), YUMM1.1 (1 × 106 cells) or UV YUMM1.1–9 (1 × 106 cells) cells were resuspended in 100 ml PBS and injected subcutaneously into the dorsal flanks of the mice. At 3 weeks after cell injection, mice were killed and tumors and spleens were collected.
For Treg cell depletion, 3 d after TAM and every week, 250 μg of CD25 (clone PC-61.5.3; BE0012, BioXCell) antibody was injected intraperitoneally into Atg7Δ/Δ and Atg7+/+ hosts. At 4 d after the first antibody injection, MB49 (0.25 × 106 cells) cells were resuspended in 100 ml PBS and injected subcutaneously into the dorsal flanks of the mice. At 3 weeks after cell injection, mice were killed and tumors and spleens were collected.
Poillet-Perez L., Sharp D.W., Yang Y., Laddha S.V., Ibrahim M., Bommareddy P.K., Sherrie Hu Z., Vieth J., Haas M., Bosenberg M.W., Rabinowitz J.D., Cao J., Guan J.L., Ganesan S., Chan C.S., Mehnert J.M., Lattime E.C, & White E. (2020). Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response. Nature cancer, 1(9), 923-934.
+ Open protocol
+ Expand
3

VH1-2 rearranging germline mouse model

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice expressing the VH1-2 rearranging germline and the rearranged gl-VRC01 light chain were engineered as previously described45 (link), with the additional substitution of mouse JH1-4 with human JH2 segment45 (link). For immunization studies, mice were immunized sequentially with 25 µg of protein per animal in 60 µg of Poly I:C adjuvant (Invivogen) at two sites intramuscularly. For antibody coadministration 250 µg of anti-CTLA-4(BioXCell #BE0131), anti-OX-40 (BioXCell #BE0031) or a combination of isotype controls (Syrian Hamster IgG (BioXCell #BE0087) + Rat IgG2a (BioXCell #BE0089)). Mice were harvested at week 11 and spleen, lymph node and blood were isolated. All mice used in this study were housed in the Medical Sciences Research Building II Vivarium at Duke University Medical center in a pathogen-free environment with 12-h light/datk cycles at 20–25 ˚C, in accordance with Duke University Institutional Animal Care and Use Committee-approved animal protocols. All aspects of the procurement, conditioning/quarantine, housing, colony management, veterinary care, and carcass disposal programs comply with the guidelines set forth by the NIH guide for the care and use of laboratory animals, the Animal Welfare Act, and all applicable federal, state and institutional laws.
Bradley T., Kuraoka M., Yeh C.H., Tian M., Chen H., Cain D.W., Chen X., Cheng C., Ellebedy A.H., Parks R., Barr M., Sutherland L.L., Scearce R.M., Bowman C.M., Bouton-Verville H., Santra S., Wiehe K., Lewis M.G., Ogbe A., Borrow P., Montefiori D., Bonsignori M., Anthony Moody M., Verkoczy L., Saunders K.O., Ahmed R., Mascola J.R., Kelsoe G., Alt F.W, & Haynes B.F. (2020). Immune checkpoint modulation enhances HIV-1 antibody induction. Nature Communications, 11, 948.
+ Open protocol
+ Expand
4

Tumor Growth Modulation by Cell Depletion

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD8 þ T cells, CD4 þ T cells, and macrophages were depleted during EL4 tumor growth by intraperitoneal injection of 200 mg of anti-IgG2b control (BE0090, Bioxcell), anti-CD8 [(YTS169), BE0117, Bioxcell], 300 mg of anti-CD4 [(GK1.5), BE003-1, Bioxcell], or anti-CSF1R [(AFS98), BE0213, Bioxcell], respectively, every two to three days, starting one day prior to tumor inoculation.
Park J., Lee S.Y., Jeon Y., Kim K.M., Lee J.K., Ko J., Park E.J., Yoon J.S., Kang B.E., Ryu D., Lee H., Shin S.J., Go H, & Lee C.W. (2022). The Pellino1-PKCθ Signaling Axis Is an Essential Target for Improving Antitumor CD8+ T-lymphocyte Function. Cancer immunology research, 10(3).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!